Lawmakers and some investors are warning about the growing reliance of US pharmaceutical companies on China, raising the prospect of national security restrictions on investments in Chinese biotechs.Pfizer has become the latest US drug giant to announce an agreement with a Chinese biotech to work together on medicines. Pfizer said on Thursday it would pay $650mn to Suzhou-based Innovent Biologics for several cancer drugs. The deal is worth up to $10.5bn to Innovent if commercial and regulatory targets are hit.
立法者和一些投资者就美国制药公司日益依赖manbetx3.0 发出警告，这引发了美国可能以国家安全为由限制投资manbetx3.0 生物技术公司的前景。
您已阅读8%（573字），剩余92%（6790字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。